Antibiotic Selection Guidelines

Introduction to Antibiotic Selection

The Indian Council of Medical Research recommends selecting antibiotics according to the type of infection, severity, and local resistance patterns, with specific first and second-line options for each condition 1, 2

For impetigo, the first choice of antibiotics includes oral dicloxacillin, cefalexin, erythromycin, clindamycin, or amoxicillin-clavulanic acid 1
For purulent skin and soft tissue infections likely caused by Staphylococcus aureus, the first choice includes dicloxacillin, cefazolin, clindamycin, cefalexin, doxycycline, or sulfamethoxazole-trimethoprim 1
For MRSA infections, the first choice includes vancomycin, linezolid, clindamycin, daptomycin, ceftaroline, doxycycline, or sulfamethoxazole-trimethoprim 1
Evidence shows better clinical cure with linezolid compared to vancomycin (OR, 1.41; 95% CI, 1.03-1.95) 3
For non-purulent skin and soft tissue infections, the first choice includes benzylpenicillin or phenoxymethylpenicillin, clindamycin, nafcillin, cefazolin, or cefalexin 3
For necrotizing fasciitis, the first choice includes vancomycin or linezolid plus piperacillin-tazobactam or a carbapenem, or ceftriaxone and metronidazole 3

For mild to moderate intra-abdominal infections, the first choice includes amoxicillin-clavulanic acid or ampicillin + gentamicin + metronidazole (in children) 2, 4
For severe intra-abdominal infections, the first choice includes cefotaxime or ceftriaxone + metronidazole, or piperacillin-tazobactam 2, 4
For hospital-acquired infections in critically ill patients, the first choice includes piperacillin, tigecycline, or a carbapenem (meropenem, imipenem, or doripenem) 5

For non-severe community-acquired pneumonia (CAP), the first choice includes penicillin G, aminopenicillin + macrolides, co-amoxiclav + macrolides, or 2nd/3rd generation cephalosporin + macrolides 6
For severe CAP, the first choice includes 3rd generation cephalosporin + macrolides 6
For CAP with risk factors for Pseudomonas aeruginosa, the first choice includes anti-pseudomonal cephalosporin 6
For COPD exacerbations, mild cases can be treated with amoxicillin or tetracyclines, while moderate to severe cases can be treated with co-amoxiclav 6

Local resistance patterns should be considered when selecting antibiotics 6
For most community-acquired infections, 5-7 days of appropriate therapy is sufficient, while more severe infections may require longer courses (10-14 days) 2, 7
Clinical effects of antibiotic treatment should be expected within 3 days, and patients should be instructed to contact their doctor if improvement is not noticeable within this timeframe 6
Common pitfalls to avoid include using fluoroquinolones as first-line therapy due to increasing resistance concerns, using clindamycin for B. fragilis infections without checking local susceptibility patterns, failing to provide adequate coverage for suspected MRSA, and using broad-spectrum antibiotics for mild infections that could be treated with narrower-spectrum agents 2, 7